JP6814730B2 - 治療用化合物およびその使用 - Google Patents
治療用化合物およびその使用 Download PDFInfo
- Publication number
- JP6814730B2 JP6814730B2 JP2017512677A JP2017512677A JP6814730B2 JP 6814730 B2 JP6814730 B2 JP 6814730B2 JP 2017512677 A JP2017512677 A JP 2017512677A JP 2017512677 A JP2017512677 A JP 2017512677A JP 6814730 B2 JP6814730 B2 JP 6814730B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- group
- compound
- alkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(*)(C(*)*C(C(N1*)=O)=NN(*)C1=O)N([Re])[Re] Chemical compound CC(*)(C(*)*C(C(N1*)=O)=NN(*)C1=O)N([Re])[Re] 0.000 description 24
- DEJNTILJOGNTAQ-UHFFFAOYSA-N CC(C)NCC(C1)N(C)Cc2c1cccc2 Chemical compound CC(C)NCC(C1)N(C)Cc2c1cccc2 DEJNTILJOGNTAQ-UHFFFAOYSA-N 0.000 description 2
- RHFLXMGHOMIKBN-UHFFFAOYSA-N CC(C)NCC(c1ccc(C(F)(F)F)cc1)N(C)C Chemical compound CC(C)NCC(c1ccc(C(F)(F)F)cc1)N(C)C RHFLXMGHOMIKBN-UHFFFAOYSA-N 0.000 description 2
- VMXPDQGFVIAAMN-UHFFFAOYSA-N CC(C)NCC1N(C)CCc2ccccc12 Chemical compound CC(C)NCC1N(C)CCc2ccccc12 VMXPDQGFVIAAMN-UHFFFAOYSA-N 0.000 description 2
- BHWXYAFMHWASNK-UHFFFAOYSA-N CC(C)NCC1N(C)c2ccccc2CC1 Chemical compound CC(C)NCC1N(C)c2ccccc2CC1 BHWXYAFMHWASNK-UHFFFAOYSA-N 0.000 description 2
- BIBOWUAGEFHFBT-UHFFFAOYSA-N CC(C)NCCN(C)CC(F)(F)F Chemical compound CC(C)NCCN(C)CC(F)(F)F BIBOWUAGEFHFBT-UHFFFAOYSA-N 0.000 description 2
- MEEHVVGTARIBOZ-UHFFFAOYSA-N CCCNCC(c1cccc(Cl)c1)N(C)C Chemical compound CCCNCC(c1cccc(Cl)c1)N(C)C MEEHVVGTARIBOZ-UHFFFAOYSA-N 0.000 description 2
- DABATEFTZLWJBQ-UHFFFAOYSA-N CCNCC(C)(c1ccccc1)N(C)C Chemical compound CCNCC(C)(c1ccccc1)N(C)C DABATEFTZLWJBQ-UHFFFAOYSA-N 0.000 description 2
- RBQDUHNRCGKRLO-UHFFFAOYSA-N CN(C)C(CNN=C)c(cc1)ccc1OC Chemical compound CN(C)C(CNN=C)c(cc1)ccc1OC RBQDUHNRCGKRLO-UHFFFAOYSA-N 0.000 description 2
- ALJLAGYCMBXNKO-UHFFFAOYSA-N CN(C)CCN(C)N Chemical compound CN(C)CCN(C)N ALJLAGYCMBXNKO-UHFFFAOYSA-N 0.000 description 2
- BDGGKPZSKHIFAE-NCXKZPMSSA-N CN(C)[C@H](CCCC1)/C1=N/C Chemical compound CN(C)[C@H](CCCC1)/C1=N/C BDGGKPZSKHIFAE-NCXKZPMSSA-N 0.000 description 2
- PYDXFSZUMHNTLD-UHFFFAOYSA-N CNCC(Cc1ccccc1)N(C)C Chemical compound CNCC(Cc1ccccc1)N(C)C PYDXFSZUMHNTLD-UHFFFAOYSA-N 0.000 description 2
- PVFIKWLTVKSXED-UHFFFAOYSA-N CNCCN(C)Cc1ccccc1 Chemical compound CNCCN(C)Cc1ccccc1 PVFIKWLTVKSXED-UHFFFAOYSA-N 0.000 description 2
- DRNLCQNBOWGWJW-DYVFJYSZSA-N C[C@H]([C@@H](c(cc1)ccc1S(c1ccccc1)(=O)=O)N(C)C)NN Chemical compound C[C@H]([C@@H](c(cc1)ccc1S(c1ccccc1)(=O)=O)N(C)C)NN DRNLCQNBOWGWJW-DYVFJYSZSA-N 0.000 description 2
- AEBWATHAIVJLTA-UHFFFAOYSA-N C(C1)CC2C1CCC2 Chemical compound C(C1)CC2C1CCC2 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- VHKNZTWMVNWAOC-UHFFFAOYSA-N CC(C)(C)OC(N1C(CN)c2ccccc2CC1)=O Chemical compound CC(C)(C)OC(N1C(CN)c2ccccc2CC1)=O VHKNZTWMVNWAOC-UHFFFAOYSA-N 0.000 description 1
- YLQNUDANNPHWQJ-UHFFFAOYSA-N CCNCC(C1)N(C)Cc2c1cccc2 Chemical compound CCNCC(C1)N(C)Cc2c1cccc2 YLQNUDANNPHWQJ-UHFFFAOYSA-N 0.000 description 1
- HJFSVWNXLZQNIQ-UHFFFAOYSA-N CN(C(C(NCCNc1ccccc1)=NN1C)=O)C1=O Chemical compound CN(C(C(NCCNc1ccccc1)=NN1C)=O)C1=O HJFSVWNXLZQNIQ-UHFFFAOYSA-N 0.000 description 1
- ZMRJZWYPYWDNTB-UHFFFAOYSA-N CN(C(CNC(C(N1C)=O)=NN(C)C1=O)CC1)c2c1cccc2 Chemical compound CN(C(CNC(C(N1C)=O)=NN(C)C1=O)CC1)c2c1cccc2 ZMRJZWYPYWDNTB-UHFFFAOYSA-N 0.000 description 1
- YSLHTWNOQJELRO-UHFFFAOYSA-N CN(C)C(CCC1)CN1C=C Chemical compound CN(C)C(CCC1)CN1C=C YSLHTWNOQJELRO-UHFFFAOYSA-N 0.000 description 1
- SOWWBSFBUDYICN-UHFFFAOYSA-N CN(C)C(CNC(C(N1C)=O)=NN(C)C1=O)c(cc1)ccc1F Chemical compound CN(C)C(CNC(C(N1C)=O)=NN(C)C1=O)c(cc1)ccc1F SOWWBSFBUDYICN-UHFFFAOYSA-N 0.000 description 1
- CRIJBKOELFHRKA-UHFFFAOYSA-N CN(CCNC(C(N1C)=O)=NN(C)C1=O)CC(F)(F)F Chemical compound CN(CCNC(C(N1C)=O)=NN(C)C1=O)CC(F)(F)F CRIJBKOELFHRKA-UHFFFAOYSA-N 0.000 description 1
- LZMZGFOHMNVTPE-UHFFFAOYSA-N CN(CCNN=C)CC(F)(F)F Chemical compound CN(CCNN=C)CC(F)(F)F LZMZGFOHMNVTPE-UHFFFAOYSA-N 0.000 description 1
- DGENMXWRFONJEM-UHFFFAOYSA-N CN1C(CNC(C(N2C)=O)=NN(C)C2=O)CCC1 Chemical compound CN1C(CNC(C(N2C)=O)=NN(C)C2=O)CCC1 DGENMXWRFONJEM-UHFFFAOYSA-N 0.000 description 1
- REHZNCOQCHRKRQ-NUHJPDEHSA-N C[C@@H](C(C=C)OC)S(c1ccccc1)(=O)=O Chemical compound C[C@@H](C(C=C)OC)S(c1ccccc1)(=O)=O REHZNCOQCHRKRQ-NUHJPDEHSA-N 0.000 description 1
- GLFUIFIITBVKHL-WCQYABFASA-N C[C@@H]([C@H](c1ccccc1)N(C)C)NN1CC1 Chemical compound C[C@@H]([C@H](c1ccccc1)N(C)C)NN1CC1 GLFUIFIITBVKHL-WCQYABFASA-N 0.000 description 1
- YTSXQQHDIDSZDJ-UHFFFAOYSA-N [O-][N+](S(c1ccccc1)#[O])=O Chemical compound [O-][N+](S(c1ccccc1)#[O])=O YTSXQQHDIDSZDJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046770P | 2014-09-05 | 2014-09-05 | |
| US62/046,770 | 2014-09-05 | ||
| PCT/US2015/048174 WO2016036873A1 (en) | 2014-09-05 | 2015-09-02 | Therapeutic compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525740A JP2017525740A (ja) | 2017-09-07 |
| JP2017525740A5 JP2017525740A5 (enExample) | 2018-10-11 |
| JP6814730B2 true JP6814730B2 (ja) | 2021-01-20 |
Family
ID=54140703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512677A Expired - Fee Related JP6814730B2 (ja) | 2014-09-05 | 2015-09-02 | 治療用化合物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10358437B2 (enExample) |
| EP (1) | EP3189046B1 (enExample) |
| JP (1) | JP6814730B2 (enExample) |
| CN (1) | CN107074823B (enExample) |
| WO (1) | WO2016036873A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3189049B1 (en) | 2014-09-05 | 2024-03-20 | Genentech, Inc. | Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer |
| CN107406429B (zh) | 2015-01-09 | 2021-07-06 | 基因泰克公司 | 哒嗪酮衍生物及其在治疗癌症中的用途 |
| CN110117271A (zh) * | 2018-02-06 | 2019-08-13 | 中国科学院上海药物研究所 | 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
| TWI884745B (zh) * | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020160193A2 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021022163A2 (en) * | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| KR102085758B1 (ko) * | 2019-08-05 | 2020-03-06 | 연세대학교 산학협력단 | 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| AU2023333181A1 (en) | 2022-09-02 | 2025-03-13 | Auron Therapeutics, Inc. | Pyridazinon derivatives as kat2 degraders for the treatment of proliferative disorders |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| FR2707294B1 (fr) * | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| KR100441557B1 (ko) | 1994-07-21 | 2005-08-05 | 아크조 노벨 엔.브이. | 고리형케톤과산화물조성물 |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| CN1160338C (zh) | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| WO2006003147A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as parp inhibitors |
| FR2882750B1 (fr) * | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| FR2933979B1 (fr) * | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| JP2013528180A (ja) * | 2010-05-28 | 2013-07-08 | ジーイー・ヘルスケア・リミテッド | 放射性標識化合物及びその製造方法 |
| JP6099669B2 (ja) * | 2011-12-20 | 2017-03-22 | サノフイ | イソチアゾロピリジン−２−カルボキサミドおよび医薬としてそれらの使用 |
| UY35103A (es) | 2012-10-29 | 2014-05-30 | Glaxo Group Ltd | Compuestos de cefem 2-sustituidos |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| CA2906100A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Treating th2-mediated diseases by inhibition of bromodomains |
| EP3189049B1 (en) | 2014-09-05 | 2024-03-20 | Genentech, Inc. | Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer |
| CN107406429B (zh) | 2015-01-09 | 2021-07-06 | 基因泰克公司 | 哒嗪酮衍生物及其在治疗癌症中的用途 |
-
2015
- 2015-09-02 CN CN201580059718.0A patent/CN107074823B/zh not_active Expired - Fee Related
- 2015-09-02 JP JP2017512677A patent/JP6814730B2/ja not_active Expired - Fee Related
- 2015-09-02 WO PCT/US2015/048174 patent/WO2016036873A1/en not_active Ceased
- 2015-09-02 EP EP15763755.4A patent/EP3189046B1/en active Active
-
2017
- 2017-03-03 US US15/449,706 patent/US10358437B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170334883A1 (en) | 2017-11-23 |
| US10358437B2 (en) | 2019-07-23 |
| EP3189046B1 (en) | 2020-08-26 |
| EP3189046A1 (en) | 2017-07-12 |
| CN107074823A (zh) | 2017-08-18 |
| WO2016036873A1 (en) | 2016-03-10 |
| CN107074823B (zh) | 2021-05-04 |
| JP2017525740A (ja) | 2017-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6669744B2 (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| JP7160688B2 (ja) | Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用 | |
| US10150767B2 (en) | Therapeutic compounds and uses thereof | |
| JP6767969B2 (ja) | がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体 | |
| JP6847844B2 (ja) | 治療用ピリダジン化合物およびその使用 | |
| JP6639497B2 (ja) | ブロモドメインインヒビターおよびその使用 | |
| JP6820254B2 (ja) | 治療用化合物およびその使用 | |
| CN107074823B (zh) | 治疗性化合物及其用途 | |
| JP6659703B2 (ja) | ピリダジノン誘導体および癌の処置におけるそれらの使用 | |
| JP6709792B2 (ja) | 治療用化合物およびその使用 | |
| HK1242696A1 (en) | Therapeutic compounds and uses thereof | |
| HK1247193A1 (en) | Pyridazinone derivatives and their use in the treatment of cancer | |
| HK1242696B (en) | Therapeutic compounds and uses thereof | |
| HK1242695A1 (en) | Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer | |
| HK1247193B (en) | Pyridazinone derivatives and their use in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180831 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180831 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190510 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190509 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190807 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191009 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200210 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200710 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200820 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201120 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201127 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201221 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6814730 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |